The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000740392
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
18/05/2026
Date registered
Help: Date registered
19/06/2026
Date last updated
Help: Date last updated
29/09/2026
Date data sharing statement initially provided
Help: Data sharing statement date
19/06/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
The PROTECT-PD Study: Evaluating Probucol's preliminary efficacy on disease progression in Parkinson's disease - Cohort 1.
Scientific title
The PROTECT-PD Study: Evaluating Probucol's preliminary efficacy on disease progression in Parkinson's disease - A randomised, double-blind, placebo-controlled, multicentre trial
Additional trial identifiers [1] 317141 0
None
Universal Trial Number (UTN)
Trial acronym
PRO-PD2025
Related trial records

Health condition
Health condition(s) studied:
Parkinson's Disease 341719 0
Condition category
Condition code
Neurological 337797 337797 0 0
Parkinson's disease

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
PROTECT-PD is a randomised controlled research trial examining whether intervention with Probucol supports motor symptom progression within PD. Participants are randomly assigned to one of two groups, group 1 (treatment) or group 2 (placebo).

Group 1 (Treatment):
Chemical name: 4,4’-[Propan-2,2-diylbis(sulfandiyl)]bis[2,6-bis(1,1- dimethylethyl) phenol]
The proposed dose of Probucol for this protocol adopts contemporary usage published in contemporary clinical trials at 250 mg twice a day. Probucol will be supplied in a commercially available form known as Lorelco and taken as capsules orally.

Study medication will commence (day 1, week 1) with a single dose escalation design with all participants receiving initially for two-weeks 1 X placebo per day (once daily). Unused medication is to be returned at every visit to monitor drug compliance.

Subjects will be dosed as:
• Placebo lead-in (Weeks 1 and 2): ALL participants (both the treatment group and the placebo group) receive ONE placebo capsule taken orally ONCE DAILY in the morning, with food. No active study drug (Lorelco) is administered during this 2-week lead-in period. This phase acclimatises participants to the dosing schedule before randomised treatment begins.
• Week 3: 1 x 250 mg Lorelco™ (or matching placebo) taken orally once daily in the morning, with food.
• Week 4 – 78: 1 x 250 mg Lorelco™ (or matching placebo) taken in the morning, with food. 1 x 250 mg Lorelco™ taken in the evening, with food (total dose: 500 mg/day). Unused medication is to be returned at every visit to monitor drug compliance.
Intervention code [1] 333910 0
Treatment: Drugs
Description of the comparator or control
Placebo composition: opaque capsules with no active ingredients and a filler of microcrystalline cellulose.
Study medication will commence (day 1, week 1) with a single dose escalation design with all participants receiving initially for two-weeks 1 X placebo per day. Unused capsules are to be returned to monitor drug compliance.
Group 2 (placebo)
Subjects will be dosed as:
• Week 3: 1 x matching placebo taken in the morning, with food.
• Week 4 – 78: 1 x matching placebo taken in the morning, with food. 1 x matching placebo taken in the evening, with food.
Unused capsules are to be returned at every visit to monitor drug compliance.
Control group
Placebo

Outcomes
Primary outcome [1] 345243 0
To evaluate the preliminary efficacy of 250 mg b.d. Lorelco™ on motor symptom progression as measured by change in the Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III in Parkinson’s patients over a 78-week treatment period
Timepoint [1] 345243 0
Assessments will be conducted at baseline, week 26, week 52, and week 78.
Secondary outcome [1] 462310 0
To assess the effect of 250 mg b.d. Lorelco on non-motor symptoms of daily living and motor complications in Parkinson's patients over 78 weeks. This will be assessed as a composite outcome
Timepoint [1] 462310 0
Assessed at baseline, week 26, week 52, and week 78.
Secondary outcome [2] 462311 0
To assess the effect of 250 mg b.d. Lorelco on motor aspects of daily living in Parkinson's patients over 78 weeks.
Timepoint [2] 462311 0
Assessed at baseline, week 26, week 52, and week 78.
Secondary outcome [3] 462312 0
To assess the effect of 250 mg b.d. Lorelco on cognitive function in Parkinson's patients over 78 weeks.
Timepoint [3] 462312 0
Assessed at baseline, week 26, week 52, and week 78.
Secondary outcome [4] 462313 0
To assess the effect of 250 mg b.d. Lorelco on functional mobility and gait in Parkinson's patients over 78 weeks. This will be assessed as a composite outcome
Timepoint [4] 462313 0
Assessed at baseline, week 26, week 52, and week 78.
Secondary outcome [5] 462314 0
To assess the effect of 250 mg b.d. Lorelco on depressive symptoms in Parkinson's patients over 78 weeks.
Timepoint [5] 462314 0
Assessed at baseline, week 26, week 52, and week 78.
Secondary outcome [6] 462315 0
To assess the effect of 250 mg b.d. Lorelco on overall non-motor symptom burden in Parkinson's patients over 78 weeks
Timepoint [6] 462315 0
Assessed at baseline, week 26, week 52, and week 78.
Secondary outcome [7] 462316 0
To assess the effect of 250 mg b.d. Lorelco on health-related quality of life in Parkinson's patients over 78 weeks.
Timepoint [7] 462316 0
Assessed at baseline, week 26, week 52, and week 78.
Secondary outcome [8] 462319 0
To assess the effect of 250 mg b.d. Lorelco on patient-reported Parkinson's disease symptom burden over 78 weeks.
Timepoint [8] 462319 0
Assessed at baseline, week 26, week 52, and week 78.
Secondary outcome [9] 462320 0
To explore the effect of 250 mg b.d. Lorelco on plasma biomarkers relevant to Parkinson's disease pathology.
Timepoint [9] 462320 0
Assessed at baseline, week 26, week 52, and week 78.
Secondary outcome [10] 462321 0
To assess changes in motor, cognitive and speech function through video, audio and keyboard-based tasks using the TAS Test Protocol, assessed as a composite secondary outcome.
Timepoint [10] 462321 0
Baseline, week 26, week 52, and week 78.
Secondary outcome [11] 462326 0
To assess the safety and tolerability of Probucol (Lorelco) in patients with Parkinson's disease, assessed as a composite secondary outcome.
Timepoint [11] 462326 0
Adverse events: assessed continuously from baseline through to end of week 78; all ongoing adverse events followed to resolution or stabilisation. Reported at clinic visits at weeks 1, 3, 4, 5, 15, 26, 39, 52, 65, 78, and at follow-up (week 82), and may be reported between visits at any time. ECG parameters: assessed at screening, weeks 1, 3, 4, 5, 15, 26, 39, 52, 65, 78, and week 82. Vital signs (blood pressure, heart rate, body temperature): assessed at screening, weeks 1, 3, 4, 5, 15, 26, 39, 52, 65, 78, and week 82. Body weight: assessed at screening, weeks 1, 3, 4, 5, 15, 26, 39, 52, 65, 78, and week 82. Physical examination: full examination at screening, baseline (week 3), and week 78; targeted examination at other visits as clinically indicated. Clinical laboratory parameters (haematology, serum chemistry, liver function, lipid panel): assessed at screening, weeks 1, 3, 4, 5, 15, 26, 39, 52, 65, 78, and week 82. Coagulation profile: assessed at screening, week 78, and week 82.

Eligibility
Key inclusion criteria
Must have given written informed consent before any study-related activities are carried out and must be able to understand the full nature and purpose of the trial, including possible risks and adverse effects.
Adult males and females, greater than or equal to 40 years or above age at screening
Diagnosis of Parkinson’s Disease within three years prior to screening,
MDS-UDPRS Part III motor score of <35 at screening, assessed in the ON medication state
Montreal Cognitive Assessment score of greater than or equal to 26 at screening
Stable dose of levodopa, dopamine agonists, or other PD medications for at least 4 weeks prior to screening, with no intention to change the medication regimen during the trial period. This need not prohibit changes in medication if clinically indicated once on trial.
Able to take oral medications and willing to record daily adherence to the study drug.
Be willing and able to comply with all study assessments and adhere to the protocol
schedule and restrictions.
Minimum age
40 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
1. Hoehn and Yahr scale score of 3 or more
2. Presence of motor fluctuations of dyskinesia
3. Atypical or secondary parkinsonism.
4. History of significant drug induced QT interval prolongation.
5. Evidence of abnormal cardiac function as defined by any of the following:
a. Myocardial infarction within 6 months of Week 1, Day 1
b. Symptomatic congestive heart failure (New York Heart Association > Class II)
c. Unstable angina
d. Unstable atrial fibrillation including paroxysmal atrial fibrillation. Medicated,
stable atrial fibrillation will be assessed on a case-by-case basis
e. Frequent multifocal ventricular arrhythmia
6. Gastrointestinal conditions that, in the opinion of the Investigator, could affect the absorption of study drug.
7. Use of the below medications, supplements, or consumption of foods within 7 days of first administration of Probucol (Lorelco™), and for the duration of the study. These include (but are not limited to):
a. Strong QT prolongation inducers should be assessed on a case-by-case basis at the discretion of the investigator
b. With significant central anticholinergic effects,
c. Sedatives,
d. Any investigational treatment for PD
e. Foods: Grapefruit or Seville orange (or grapefruit- or Seville orange-containing products, including juices)
8. Current diagnosis of cancer (within 3 years) and/or undergoing chemotherapy, with exception to non-melanoma skin cancers such as basal or squamous cell carcimona in situ,
9. Significant head injury within 5 years
10. Electrolyte imbalance (e.g. on high steroids, pituitary tumours and Addison disease)
11. Hypokalaemia, hypomagnesaemia and hypocalcaemia
12. Major surgery is planned during the conduct of the trial, or a clinical event has occurred in the six months preceding study inclusion that may compromise ability to participate for the duration of the study,
13. History of stroke with residual cognitive or motor deficits
14. Current diagnosis with a psychiatric disorder such as major depression, bipolar disorder or schizophrenia where the condition is affecting daily functioning, or taking psychotropic medications
15. Other excluded medications will be those that are specifically contraindicated with Probucol, based on historic clinical indications for the treatment of cardiovascular disease.
16. Self-reported active human immunodeficiency virus (HIV-1 or HIV-2), hepatitis B (HBsAg) or hepatitis C virus (HCV).
17. Any inflammatory or chronic pain condition that necessitates regular use of opiates/opioids,
18. Major surgery within 28 days of the pre-baseline visit, or minor surgical procedures within 7 days of pre-baseline .
19. For women of childbearing potential, a hCG pregnancy test > 5 U/L at screening, or on Day 1, prior to dose administration.
20. Pregnant or breast-feeding (or planning to breastfeed) while on study through 15 days after the last dose of study drug.
21. Hypersensitivity or other clinically significant reaction to the study drug or its inactive ingredients.
22. Known substance abuse or medical, psychological, or social conditions that, in the opinion of the Investigator, may interfere with the patient’s participation in the clinical study or evaluation of the clinical study results.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
All participant IDs will be held in a de-identified format at a central administrative location. The allocation list linking IDs to treatment groups will be securely maintained by the sponsor-approved pharmacy. Only the pharmacy will have access to group assignments and will only release this information if required, such as in the case of a serious adverse event.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Participants will be assigned to either the active treatment or placebo arm in a 1:1 ratio using permuted block randomisation. Allocation will be conducted via a computer-generated process linked to each participant’s unique study ID. These IDs will be created and assigned in a random sequence.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
WA
Recruitment hospital [1] 29445 0
Perron Institute for Neurological and Translational Science - Nedlands
Recruitment postcode(s) [1] 45765 0
6009 - Nedlands

Funding & Sponsors
Funding source category [1] 321724 0
Other
Name [1] 321724 0
Perron Institute for Neurological and Translational Science
Country [1] 321724 0
Australia
Primary sponsor type
University
Name
Curtin University
Address
Country
Australia
Secondary sponsor category [1] 324557 0
None
Name [1] 324557 0
Address [1] 324557 0
Country [1] 324557 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320256 0
Bellberry Human Research Ethics Committee C
Ethics committee address [1] 320256 0
Ethics committee country [1] 320256 0
Australia
Date submitted for ethics approval [1] 320256 0
07/10/2025
Approval date [1] 320256 0
12/11/2025
Ethics approval number [1] 320256 0
HREC 2025-10-1656

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 149914 0
Dr Wai Yan Yau
Address 149914 0
Perron Institute for Neurological and Translational Science. 8 Verdun Street, Perth, WA 6009
Country 149914 0
Australia
Phone 149914 0
+61 402811690
Fax 149914 0
Email 149914 0
Contact person for public queries
Name 149915 0
Dr Virginie Lam
Address 149915 0
Curtin University, Kent St Bentley, WA, 6102
Country 149915 0
Australia
Phone 149915 0
+61 468 532 458
Fax 149915 0
Email 149915 0
Contact person for scientific queries
Name 149916 0
Prof. John Mamo
Address 149916 0
Curtin University, Kent St Bentley, WA, 6102
Country 149916 0
Australia
Phone 149916 0
+61 08 9266 7232
Fax 149916 0
Email 149916 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.